Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNC-038 in relapsed or refractory NK/T-cell lymphoma and other NHL
NCT05627856Phase 2Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Feb 2023
- Primary completion
- Dec 2025
- Modality
- Multispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of emfizatamab in Natural killer T-cell lymphoma (NKTL), angioimmunoblastic T-cell lymphoma (AITL) and non-Hodgkin lymphoma (NHL), sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limited Toxicity at 16 days, Maximum Tolerated Dose at 16 days and 4 more. Started Feb 2023; status: active, not recruiting.
02
Drugs
emfizatamab
03
Conditions
Natural killer T-cell lymphoma (NKTL)angioimmunoblastic T-cell lymphoma (AITL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05627856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05627856.